Protara Therapeutics, Inc. 8-K

What Happened Protara Therapeutics, Inc. announced in a Form 8-K filed June 29, 2026 that Chief Medical Officer Leonardo Viana Nicacio, M.D. resigned effective June 26, 2026 to "explore other opportunities." The company said Dr. Nicacio’s duties will be subsumed by Carla Beckham, M.D., the Lead Medical Director and Head of Clinical Development, under the oversight of Jacqueline Zummo, Ph.D., Chief Research & Development Officer.

Key Details

• Filing type: Form 8-K (Item 5.02 — Departure of Directors or Certain Officers), filed June 29, 2026.
• Effective date of resignation: June 26, 2026.
• Interim coverage: Clinical and CMO responsibilities assigned to Carla Beckham, M.D., with oversight by Jacqueline Zummo, Ph.D.
• No additional arrangements or compensation details were disclosed in the filing.

Why It Matters Executive changes at the clinical leadership level can affect development programs and regulatory interactions. Protara has immediately reassigned Dr. Nicacio’s responsibilities internally, which signals continuity in clinical oversight while the company evaluates longer-term staffing. Investors should note the date and reassignment but monitor future disclosures for any updates on a permanent CMO appointment or changes to clinical development plans.